-
Product Insights
NewEsophageal Squamous Cell Carcinoma (ESCC) – Drugs In Development, 2024
Empower your strategies with our Esophageal Squamous Cell Carcinoma (ESCC) – Drugs In Development, 2024 report and make more profitable business decisions. Esophageal squamous cell carcinoma (ESCC) is a type of cancer that arises from the squamous cells lining the esophagus, the muscular tube connecting the throat to the stomach. Commonly associated with tobacco and alcohol use, as well as dietary factors, ESCC is prevalent in certain geographic regions. Symptoms often manifest late and include difficulty swallowing, weight loss, and chest...
-
Product Insights
NewMarginal Zone B-cell Lymphoma – Drugs In Development, 2024
Empower your strategies with our Marginal Zone B-cell Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Marginal zone B-cell lymphoma is a slow-growing, non-Hodgkin lymphoma that originates from B cells at the margins of lymphoid tissues. It's divided into three subtypes: extranodal, nodal, and splenic, each with distinct features. Extranodal marginal zone lymphoma primarily affects organs outside the lymph nodes, such as the stomach (gastric MALT lymphoma) or the eye (ocular MALT lymphoma). Symptoms may include...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Disufenton Sodium in High-Grade Glioma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Disufenton Sodium in High-Grade Glioma Drug Details: Disufenton sodium (NXY-059, OKN-007) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMC-002 in Gallbladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMC-002 in Gallbladder Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMC-002 in Gallbladder Cancer Drug Details: IMC-002 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Danburstotug in Esophageal Squamous Cell Carcinoma (ESCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Danburstotug in Esophageal Squamous Cell Carcinoma (ESCC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Danburstotug in Esophageal Squamous Cell Carcinoma (ESCC) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MB-106 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MB-106 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MB-106 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Drug Details: MB-106...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ecubectedin in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ecubectedin in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Ecubectedin in Solid Tumor Drug Details:Ecubectedin (PM-14) is under development for the treatment...
-
Product Insights
Colorectal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Colorectal Cancer Pipeline Products Market Report Overview Colorectal cancer starts in the colon or the rectum. It begins as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools, and weight loss with no known reasons. Risk factors for colorectal cancer include smoking, heavy alcohol use, inflammatory bowel disease (IBD), and family history. Treatment...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – IMC-002
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry IMC-002 Drug Details IMC-002 is under development for the treatment of solid tumors including...
-
Sector Analysis
Contract Manufacturing Service Agreements – Rising Manufacturing Opportunities Driven by Pharmaceutical Pipeline Expansion
This report is a brand new publication covering contract service agreements, across a range of different services and manufacturing scales. The number of contract service agreements secured serves as a primary indicator of a CMO's performance. Contract Manufacturing Service Agreements is critical for establishing an understanding of the overall CMO industry, the range of services provided and the features of some of the largest CMOs participating in the industry.